221 filings
Page 5 of 12
424B5
jko8y172ts5 huebw1r
8 Sep 20
Prospectus supplement for primary offering
4:42pm
8-K
kws18qog7mw9sxghlxq
8 Sep 20
Athenex’s oral paclitaxel plus encequidar is being evaluated in combination with GSK’s dostarlimab in the neoadjuvant chemotherapy setting
9:16am
S-8
3nzjx62nn3xnv14
6 Aug 20
Registration of securities for employees
4:32pm
S-3ASR
cackpm3v2w3
6 Aug 20
Automatic shelf registration
4:31pm
8-K
g254ijh0a3q3im02qplt
6 Aug 20
Entry into a Material Definitive Agreement
7:00am
8-K
vt3z6t
22 Jun 20
Entry into a Material Definitive Agreement
7:44am
8-K
rhonkhziql vyu9482
10 Jun 20
Departure of Directors or Certain Officers
12:00pm
CT ORDER
607v9d5ne0npag9urahw
14 May 20
Confidential treatment order
2:12pm
CT ORDER
jzqqicyca8ysi0xi58a
13 May 20
Confidential treatment order
4:19pm
8-K
7qxdl0v
7 May 20
Results of Operations and Financial Condition
7:03am
8-K
wuq1wwa
30 Mar 20
Departure of Directors or Certain Officers
4:30pm
8-K
rhmh0lw5khh7o l8
27 Feb 20
Provides Corporate Update
7:31am
S-3ASR
nynu701d
28 Jan 20
Automatic shelf registration
12:00am
8-K
jj36x65
16 Dec 19
Entry into a Material Definitive Agreement
7:01am
8-K
lf7i727kufn
13 Dec 19
Regulation FD Disclosure
4:16pm
8-K
t1v3vo8wi9j
13 Dec 19
Athenex Announces Superior Response and Survival with Lower Neuropathy of a Novel Oral
8:30am